Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
552 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01602406 | Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer | completed | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT01822613 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 |
| NCT01854606 | Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma(COEB071X2103) | completed | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT02988440 | Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT02088684 | Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | completed | Phase 1 | 70 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT02292550 | Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. | completed | Phase 1 | 27 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 17, 2020 | clinicaltrials |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | terminated | Phase 1 | 6 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT01613950 | PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT02343172 | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | completed | Phase 1 | 74 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT01948297 | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations | terminated | Phase 1 | 77 | Debiopharm International SAINDUSTRY | 5 | Sep 9, 2020 | clinicaltrials |
| NCT02271516 | to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage | terminated | Phase 1 | 3 | National Atomic Research Institute, TaiwanOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT02955251 | A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors | completed | Phase 1 | 61 | AbbVieINDUSTRY | 4 | Jul 20, 2020 | clinicaltrials |
| NCT03256331 | Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients | terminated | Phase 1 | 23 | Belx Bio-Pharmaceutical (Taiwan) CorporationINDUSTRY | 1 | Jun 1, 2020 | clinicaltrials |
| NCT03468751 | Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Henlix, IncINDUSTRY | 1 | Jun 1, 2020 | clinicaltrials |
| NCT04169178 | Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status | unknown | Phase 1 | 98 | Henlix, IncINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT04361409 | Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 10 | China Medical University HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT02058381 | A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer(B-YOND) | completed | Phase 1 | 40 | Novartis PharmaceuticalsINDUSTRY | 4 | Mar 9, 2020 | clinicaltrials |
| NCT02401542 | Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-21) | terminated | Phase 1 / Phase 2 | 71 | Rainier TherapeuticsINDUSTRY | 9 | Mar 9, 2020 | clinicaltrials |
| NCT04298333 | Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer | completed | Phase 1 | 18 | Meabco A/SINDUSTRY | 3 | Mar 6, 2020 | clinicaltrials |
| NCT02875093 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | terminated | Phase 1 | 23 | Polaris GroupINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00747474 | Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors | completed | Phase 1 | 54 | Taiwan Liposome CompanyINDUSTRY | 2 | Nov 18, 2019 | clinicaltrials |
| NCT02000947 | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer(D4190C00006) | completed | Phase 1 | 459 | MedImmune LLCINDUSTRY | 9 | Oct 31, 2019 | clinicaltrials |
| NCT01004224 | A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | completed | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 14 | Oct 4, 2019 | clinicaltrials |
| NCT02814461 | The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | completed | Phase 1 | 9 | Shin Kong Wu Ho-Su Memorial HospitalOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02648490 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | completed | Phase 1 | 19 | Henlix, IncINDUSTRY | 2 | Jul 30, 2019 | clinicaltrials |
| NCT03494231 | A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 5 | Henlix, IncINDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT04035096 | The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients | unknown | Phase 1 / Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT00969553 | Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers | completed | Phase 1 | 59 | Boehringer IngelheimINDUSTRY | 1 | Jul 26, 2019 | clinicaltrials |
| NCT02559934 | Multiple-dose Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis | completed | Phase 1 | 12 | G&E Herbal Biotechnology Co., LTDINDUSTRY | 1 | Jul 15, 2019 | clinicaltrials |
| NCT01800630 | Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas | completed | Phase 1 | 37 | InnoPharmax Inc.INDUSTRY | 1 | Jul 8, 2019 | clinicaltrials |
| NCT00912275 | Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 46 | National Taiwan University HospitalOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT02350868 | Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment | completed | Phase 1 | 23 | Taipei Medical UniversityOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT03013881 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers | completed | Phase 1 | 18 | United BioPharmaINDUSTRY | 1 | Apr 3, 2019 | clinicaltrials |
| NCT02703298 | Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients | completed | Phase 1 | 19 | TaiRx, Inc.INDUSTRY | 1 | Mar 28, 2019 | clinicaltrials |
| NCT02048488 | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 72 | Tesaro, Inc.INDUSTRY | 5 | Mar 26, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT02191878 | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 43 | Arbutus Biopharma CorporationINDUSTRY | 6 | Jan 16, 2019 | clinicaltrials |
| NCT02069041 | A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer | completed | Phase 1 | 8 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02853565 | A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 10 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Nov 8, 2018 | clinicaltrials |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | terminated | Phase 1 / Phase 2 | 1 | Taiwan Liposome CompanyINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT02648425 | Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine | completed | Phase 1 | 31 | ASLAN PharmaceuticalsOTHER | 2 | Oct 25, 2018 | clinicaltrials |
| NCT01425996 | A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 3 | Taiwan Liposome CompanyINDUSTRY | 1 | Aug 21, 2018 | clinicaltrials |
| NCT02293850 | Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Oncolys BioPharma IncINDUSTRY | 2 | Aug 20, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT01428492 | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma(PKB115125) | completed | Phase 1 | 90 | NovartisINDUSTRY | 5 | Aug 8, 2018 | clinicaltrials |
| NCT02025114 | Selumetinib in Combination With Gefitinib in NSCLC Patients | completed | Phase 1 / Phase 2 | 34 | National Taiwan University HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development LimitedINDUSTRY | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01728311 | Open Label Study of BAY1082439 in Patients With Advanced Cancer | completed | Phase 1 | 60 | BayerINDUSTRY | 3 | Jan 30, 2018 | clinicaltrials |
| NCT03224572 | The Effect of Vitamin C on Quality of Life of Terminal Cancer Patients | unknown | Phase 1 / Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Jan 2, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials